Matthew S. Davids, MD, MMSc, discusses how efficacy data for pirtobrutinib plus venetoclax and rituximab from BRUIN CLL-322 may affect relapsed/refractory CLL management.
Matthew S. Davids, MD, MMSc, Dana-Farber Cancer Institute
Advertisement
Articles by Matthew S. Davids, MD, MMSc, Dana-Farber Cancer Institute
Matthew S. Davids, MD, MMSc, discusses key efficacy results from 2 follow-up analyses of the phase 1/2 BRUIN trial evaluating pirtobrutinib.
Following the ASH 2021 annual meeting, expert hematologist/oncologists discuss updates in chronic lymphocytic leukemia.
Shared insight on updates in the chronic myeloid leukemia treatment landscape following the ASH 2021 annual meeting.
Expert perspectives on clinical data readouts in acute lymphocytic leukemia from the ASH 2021 annual meeting.
Advertisement
Latest Updated Articles
Rapid Readouts: Five-Year Analysis of MURANO StudyDecember 23rd 2020
ASH 2021: Novel Therapy in Acute Lymphocytic LeukemiaJanuary 31st 2022
ASH 2020 Updates in Relapsed/Refractory B-Cell LymphomasJanuary 22nd 2021
ASH 2020 Updates in CLLJanuary 22nd 2021
ASH 2020 Updates in Non-CLL B-Cell LymphomasJanuary 22nd 2021
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Bioequivalent Olaparib Across Previously Approved Cancer Indications
2
FDA Approves Zidesamtinib in Pretreated ROS1+ NSCLC
3
Experts Revisit the Most Notable Data in GU Oncology From ASCO 2026
4
Dr Mardones on Giredestrant Plus Palbociclib in Estrogen Receptor+ Breast Cancer
5